Pfizer Inc and BioNTech said on Thursday they had asked US regulators to approve emergency use of their COVID-19 vaccine for children aged from five to 11, Pfizer said in a post on Twitter.

“We and BioNTech Group officially submitted our request to US FDA for Emergency Use Authorization (EUA) of our COVID-19 vaccine in children 5 to <12,” the company said.